ABS (Australian Bureau of Statistics) (2019) Microdata: National Health Survey, 2017–18, AIHW analysis of detailed microdata, accessed 28 April 2023.
AIHW (Australian Institute of Health and Welfare) (2021) Australian Burden of Disease Study 2018: Interactive data on disease burden, AIHW, Australian Government, accessed 22 May 2023.
AIHW (2022a) Australian Burden of Disease Study 2022, AIHW, Australian Government, accessed 19 May 2023. doi:10.25816/e2v0-gp02.
AIHW (2022b) Health system spending per case of disease and for certain risk factors, AIHW, Australian Government, accessed 19 May 2023.
AIHW (2023a) Australian Burden of Disease Study 2023, AIHW, Australian Government, accessed 14 December 2023.
AIHW (2023b) Disease expenditure in Australia 2020–21, AIHW, Australian Government, accessed 14 December 2023.
Capuano V, Marchese F, Capuano R, Torre S, Iannone A, Capuano E, Lamaida N, Sonderegger M and Capuano E (2017) ‘Hyperuricaemia as an independent risk factor for major cardiovascular events: a 10-year cohort study from Southern Italy’, Journal of Cardiovascular Medicine, 18(3):159-164, doi:10.2459/JCM.0000000000000347.
Chandratre P, Roddy E, Clarson L, Richardson J, Hider SL and Mallen CD (2013) ‘Health-related quality of life in gout: a systematic review’, Rheumatology Oxford, 52(11):2031–2040, doi:10.1093/rheumatology/ket265.
Graf SW, Whittle SL, Wechalekar MD, Moi JHY, Barrett C, Hill CL, Littlejohn G, Lynch N, Gabor M, Taylor AL, Buchbinder R and Zochling J (2015) ‘Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative’, International Journal of Rheumatic Diseases, 18:341–351, doi:10.1111/1756-185X.12557.
Grassi D, Ferri L, Desideri G, Di Giosia P, Cheli P, Del Pinto R, Properzi G and Ferri C (2014) ‘Chronic hyperuricaemia, uric acid deposit and cardiovascular risk’, Current Pharmaceutical Design, 19(13):2432–2438, doi:10.2174/1381612811319130011.
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger H, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Taylor W, Choi H, Singh J, Dallbeth, Kaplan S, Niyyar V, Jones D, Yarrows S, Rossler B, Kerr G, King C, Levy G, Furst D, Edwards N, Mandell B, Ralph-Schmacher H, Robbins M, Wenger N and Terkeltaub R (2012) ‘2012 American College of Rheumatology Guidelines for Management of Gout Part I: Systematic Non-pharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia’, Arthritis Care & Research, 64(10):1431–1446, doi: https://doi.org/10.1002/acr.21772.
Lindsay K, Gow P, Vanderpyl J, Logo P and Dalbeth N (2011) ‘The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach’, Journal of Clinical Rheumatology, 17(1):1–6, doi:10.1097/RHU.0b013e318204a8f9.
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, Coyfish M, Guillo S, Jansen T, Janssens H, Liote F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche A, Uhligh T, Zavada J, Zhang W, Tubach F and Bardin T (2016) ‘2016 updated EULAR evidence-based recommendation for the management of gout’, Annals of the Rheumatic Diseases, 76(1):29-42, doi:10.1136/annrheumdis-2016-209707.
Robinson PC, Taylor WJ and Dalbeth N (2015) ‘An observational study of gout prevalence and quality of care in a national Australian general practice population’, The Journal of Rheumatology, 42(9):1702–1707, doi: https://doi.org/10.3899/jrheum.150310.